PDXK

Across TCGA pan-cancer cohorts, PDXK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDXK data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PDXK mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDXK expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where PDXK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.810	0.185	.008	24	view →
CCRCC	OS	Quartile	II,III,IV	0.505	0.935	.007	21	view →
LUAD	OS	Median	All	0.757	0.912	.006	14	view →
LSCC	DFS	Median	II,III,IV	0.517	0.858	.003	11	view →
PDAC	OS	Tertile	III,IV	0.586	0.957	.019	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDXK–HNSC (DFS)

Open the HNSC breakdown →